PDF hosted at the Radboud Repository of the Radboud University Nijmegen

The following full text is a publisher’s version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/58819

Please be advised that this information was generated on 2019-04-23 and may be subject to change.
CEREBROTENDINOUS XANTHOMATOSIS

Report of two Brazilian brothers

Marcos Christiano Lange1, Viviane Flumignan Zétola2, Helio A.G. Teive3, Rosana H. Scola4 Ana Paula Trentin2, Jorge A. Zavala1, Eduardo R. Pereira1, Salmo Raskin6, Lineu C. Werneck5, Erik A. Sistermans7

ABSTRACT - Cerebrotendinous xanthomatosis is a treatable rare autosomal recessive disease characterized by lipid storage secondary to a sterol 27-hydroxylase deficiency in the formation of cholic and chenodeoxycholic acids. We describe two Brazilian brothers with cognitive impairment and chronic diarrhea. One of them also presents bilateral cataracts. Neurological findings were progressive walking deficit, limb ataxia and pyramidal signs. Both patients had bilateral Achilles tendon xanthomata. Magnetic resonance image showed signal alterations in cerebellar hemispheres. We describe these cases with molecular genetic analysis confirming diagnosis and comparing with previous literature. The CYP27A1 gene study showed a C1187T mutation on exon 6.

KEY WORDS: cerebrotendinous xanthomatosis, sterol 27-hydroxylase, CYP27A1.

CASE

Case 1 - A 47 years old white man which symptoms began at 20 years old (according to the mother's information). He presented progressive walking difficulty, becoming unable to walk fast at 40 years old. Since the beginning he presented cognitive difficulties and bilateral swelling of Achilles tendons. He presented delay of the psychomotor development and started walking by one year and a half and he acquired the capacity to run and to go up stairways just at five years of age. The mother referred that he had a history of chronic diarrhea during the childhood. She denied other family members with similar symptoms, except for the patient’s younger brother.

Physical examination disclosed no abnormalities except for bilateral swelling of Achilles tendons (Fig 1a). In the neurological examination, he presented mild mental retardation, incoherent disarthria, mild bilateral facial palsy without other findings in cranial nerves. His muscular strength was IV - in superior limbs (SL) and IV- in inferior limbs (IL) according to Medical Research Council (MRC)
rating. We noted moderate spasticity in IL, preserved trophism and increased deep tendon reflexes with bilateral Babinski sign. The sensibility was preserved and there was retraction in bilateral Aquilles tendon. The patient presented symmetrical dismetry and disdiadochocinesy in SL. The cerebellar clinical evaluation of IL was disabled by the limitation of the movements. He had also gait ataxia and walked with support.

Laboratorial exams (blood count, biochemistry, hepatic and renal function, lipid analysis and coagulation tests) were normal. The biochemical analysis for serum cholesterol level, urinary bile alcohol excretion and chenodeoxycholic acid in bile were not done. Cerebrospinal fluid (CSF) was normal. Electrocardiogram (ECG) presented overload of left ventricle. Electroencephalogram (EEG) showed mild diffuse cerebral suffering, without irritation activity. Electrophysiologic studies showed sensorimotor demyelinating polineuropathy with mild axonal characteristics (Table 1). Ophthalmologic exam evidenced atrophy of retinal pigmented epithelium and peripapillar atrophy. Magnetic resonance imaging (MRI) showed hyperintense signal in the postero-inferior segments of both cerebellar hemispheres on T2 WI and ‘FLAIR’ sequences (Fig 2a). CYP27A1 gene was sequenced according to standard and adequate techniques §. It showed homozygous mutation in exon 6 (C1183T) of the CYP27A1 gene.

Case 2 – A, 40 years old white man, case one’s brother, which according to the mother’s information, presented learning difficulty since childhood, unable to read or to write. He did not finish the basic school. At 35 years of age he began with progressive difficulty to walk and two years after he began to present bilateral swellings of Aquilles tendon. He also presented chronic diarrhea and was submitted to a bilateral cataracts surgery in the childhood. Physical examination disclosed no abnormalities except for bilateral swellings of Aquilles tendons (Fig 1b). In the neurological exam he presented mild mental retardation, moderate disarthria, visual handicap and facial palsy without other abnormalities in cranial nerves. The muscle strength was V in SL and IV+ in IL (MRC rating). Other findings were spasticity in IL with preserved trophism, increased deep tendon reflexes with bilateral Babinski and Hoffman signs. Sensibility was preserved. He had walking disturbance with ataxia and spasticity in IL.

Laboratorial exams (blood count, biochemistry, lipid
analysis, hepatic and renal function) were normal. The biochemical analysis for serum cholestanol level, urinary bile alcohol excretion and chenodeoxycholic acid in bile were not done. CSF presented mild elevation of proteins (75 mg/dl, reference: 35 to 45 mg/dl) with other values in normal limits. ECG presented overload of left camer as. EEG presented with mild diffuse cerebral suffering, without irritation activity. Electrophysiologic studies showed sensorimotor axonal polyneuropathy with mild demyelination (Table 1). He was submitted to a muscle biopsy with normal fresh frozen section (HE-trichrome, oil red O, PAS, cresyl violet and sirius red) and histoch emical reactions (ATPase, NADH, esterase, myophosphorylase, acid phosphatase, alkaline phosphatase, succinate dehydrogenase, cytochrome-C oxidase and adenylate deaminase). Ophthalmologic exam evidenced incipient cataracts without surgical indication. MRI with hyperintense signal in inferior segments of both cerebellar hemispheres on T2WI and ‘FLAIR’ (Fig 2b). Genetic analysis showed homozygous mutation in exon 6 (C1183T) of the CYP27A1 gene.

Mother’s blood was sequenced and she was a carrier of the same exon 6 CYP27A1 gene mutation.

The DNA extraction was made in Curitiba by one author (SR) and the CYP27A1 analysis was made in Nij megen, The Netherlands (EAS). In both cases we did not start any treatment due to acquisition difficulty of medication and loss of follow-up.

**DISCUSSION**

CTX was first described in two cousins, with the presence of cerebellar and pyramidal signs, pal late myndonus, cognitive disability, cataracts and tendon xanthomas, apud Bertini². The main clinical characteristics are cataracts and premature atherosclerosis, tendon xanthomas with preferential location for the Achilles tendon and neurolog ical manifestations as pyramidal signs, cerebellar ataxia, seizures, cognitive disability, dementia and peripheral neuropathy³,⁴. The findings observed in our patients were cataracts, tendon xanthomas and neurological manifestations, such as cerebel lar ataxia, pyramidal signs, cognitive disability and peripheral neuropathy suggesting CTX diagnosis. The combination of chronic diarrhea and bilateral cataracts in the childhood, described in the case 2, was pathognomonic for the disease³. Besides cataracts, other retinal abnormalities have been described in these patients as paleness of the optical disk and senile retinal degeneration, as we could see in the case 1⁵.

Behavioral disturbance as depressed or distim ic humor, irritability, appetite reduction, insomnia and fatigue can be present¹,³,⁴. Heart complications, as lipomatous hypertrophy with atrial sept thickness and lung alterations and osteoporosis were described, none was found in our patients⁵-⁹. Other manifestations have been described, such as chronic myelopathy and spastic paraplegy in asso ciation with frontal lobe dementia. The differential diagnosis must be done in patients with early-onset parkinsonism-plus, that usually is associated

<table>
<thead>
<tr>
<th>Nerve</th>
<th>Variable response</th>
<th>Case 1</th>
<th>Case 2</th>
<th>N</th>
<th>Nerve</th>
<th>Variable response</th>
<th>Case 1</th>
<th>Case 2</th>
<th>N</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median S</td>
<td>Amplitude (µV)</td>
<td>*</td>
<td>*</td>
<td>&gt;15</td>
<td>Median M</td>
<td>D-Amplitude (mV)</td>
<td>10.5</td>
<td>14.0</td>
<td>&gt;5.0</td>
</tr>
<tr>
<td></td>
<td>Latency (ms)</td>
<td>*</td>
<td>*</td>
<td>&lt;3</td>
<td>P-Amplitude (mV)</td>
<td>9.73</td>
<td>15.0</td>
<td>&gt;5.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CV (m/s)</td>
<td>*</td>
<td>*</td>
<td>&gt;49</td>
<td>D-Latency (ms)</td>
<td>5.16</td>
<td>3.66</td>
<td>&gt;4.2</td>
<td></td>
</tr>
<tr>
<td>Ulnar S</td>
<td>Amplitude (µV)</td>
<td>*</td>
<td>*</td>
<td>&gt;15</td>
<td>CV (m/s)</td>
<td>49.5</td>
<td>46.9</td>
<td>&gt;50</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Latency (ms)</td>
<td>*</td>
<td>*</td>
<td>&lt;3</td>
<td>F wave (ms)</td>
<td>32.2</td>
<td>28.0</td>
<td>&lt;31</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CV (m/s)</td>
<td>*</td>
<td>*</td>
<td>&gt;49</td>
<td>Ulnar M</td>
<td>D-Amplitude (mV)</td>
<td>9.67</td>
<td>11.1</td>
<td>&gt;5.0</td>
</tr>
<tr>
<td>Sural</td>
<td>Amplitude (µV)</td>
<td>NP</td>
<td>NP</td>
<td>&gt;6</td>
<td>P-Amplitude (mV)</td>
<td>9.0</td>
<td>10.6</td>
<td>&gt;5.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Latency (ms)</td>
<td>NP</td>
<td>NP</td>
<td>&lt;3</td>
<td>D-Latency (ms)</td>
<td>5.04</td>
<td>3.3</td>
<td>&gt;3.4</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CV (m/s)</td>
<td>NP</td>
<td>NP</td>
<td>&gt;40</td>
<td>CV (mV)</td>
<td>51.5</td>
<td>49.0</td>
<td>&gt;50</td>
<td></td>
</tr>
<tr>
<td>Radial S</td>
<td>Amplitude (µV)</td>
<td>51.3</td>
<td>35.5</td>
<td>&gt;12</td>
<td>Perineal M</td>
<td>D-Amplitude (mV)</td>
<td>2.27</td>
<td>NP</td>
<td>&gt;4.0</td>
</tr>
<tr>
<td></td>
<td>Latency (ms)</td>
<td>2.0</td>
<td>2.12</td>
<td>&lt;2.1</td>
<td>P-Amplitude (mV)</td>
<td>1.55</td>
<td>NP</td>
<td>&gt;4.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CV (m/s)</td>
<td>50.0</td>
<td>47.2</td>
<td>&gt;50</td>
<td>D-Latency (ms)</td>
<td>7.30</td>
<td>NP</td>
<td>&gt;5.6</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CV (mV)</td>
<td>27.4</td>
<td>NP</td>
<td>&gt;40</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>P-Amplitude (mV)</td>
<td>3.33</td>
<td>5.53</td>
<td>&gt;5.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>D-Latency (ms)</td>
<td>8.5</td>
<td>5.64</td>
<td>&gt;6.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CV (mV)</td>
<td>29.8</td>
<td>31.5</td>
<td>&gt;40</td>
<td></td>
</tr>
</tbody>
</table>

* no patient collaboration; CV, conduction velocity; S, sensory; M, motor; Po, posterior; D, distal; P, proximal; NP, no potentials; N, normal. Need i e electromyography was normal in Case 1 and showed chronic denervation in Case 2.
with walking disturbances, pyramidal signs, cognitive abnormalities and partial L-dopa response.\textsuperscript{10-12} The diagnosis can be confirmed by biochemical exams, which demonstrate increase of serum cholestanol level and urinary bile alcohol excretion associated with reduction of the chenodeoxycholic acid in bile.\textsuperscript{13} Because technical difficulties these tests were not done in our patients.

Molecular genetic analysis, accomplished in our patients, is obtained by the screening of CYP27A1 gene located in chromosome 2q 23. The genomic structure of CYP27A1 contains nine exons and eight introns with 18,6 kb of DNA. The mature enzyme consists of 498 amino acids and it is expressed in CNS, liver, lungs, duodenum and endothelial cells. Until now, more than 45 mutations were described in the CYP27A1 gene, usually affecting heme or adrenodoxin related domains between exons 6 and 9.\textsuperscript{1,13-15} The patients described here presented a homozygous CYP27A1 gene mutation in exon 6 (1183 C>T) that was already described in other populations.\textsuperscript{1,16}

CYP27A1 enzyme (sterol 27-hydroxylase) with two protein cofactors, adrenodoxin and adrenodoxin reductase, hydroxylates a variety of sterols at the C-27 position producing the primary bile acids (cholic and chenodeoxycholic acid).\textsuperscript{14} In normal individuals, the primary bile acid inhibits the rate-limiting step in their production, the enzyme 7α-hydroxylase (negative feedback mechanism). The gene mutation causes deficiency of the enzyme sterol 27-hydroxylase, leading to reduced synthesis of cholic acid and almost no chenodeoxycholic acid. Due to the absence of the negative feedback mechanism, the 7α-hydroxylase activity is increased, producing excessive cholesterol and cholestanol and accumulating them in many tissues with increased urine excretion of the bile alcohols.\textsuperscript{2-17} The metabolic pathway can be seen in the Figure 3.

The electrophisiologic findings from CTX patients usually show an axonal degeneration, but they commonly are described as a mixed neuropathy, as observed in our cases.\textsuperscript{1} Muscle biopsy is uncharacteristic.\textsuperscript{4} Xanthomatous lesions, lipid crystal clefts and macrophage clusters that are usually seen in the CNS, were not found in the muscle biopsies.\textsuperscript{4} MRI usually demonstrate hyperintense signal in T2 and FLAIR located preferentially in periventricular area, basal ganglia and dentate nuclei of the cerebelum, besides variable degrees of cerebral and cerebellar atrophy (Fig 2A).\textsuperscript{18-21} Brain spectroscopy demonstrates significant decreases of NAA (N-acetylaspartate) and increases of lactate MRI signals. These results suggest a brain accumulation of metabolic neurotoxins and deficiency of the mitochondrial metabolism secondary to the high levels of cholestanol and bile alcohols.\textsuperscript{21,22}

The mechanism for neurological manifestations is not known. A hypothesis suggests that this happens from an increase neuronal apoptosis caused by the cholestanol overload. The presence of apolipoprotein B in CSF indicates penetration of low-density lipoprotein particles from plasma through the blood-brain barrier. These lipoprotein particles may carry cholestanol as well as cholesterol.\textsuperscript{13} Chenodeoxycholic acid replacement therapy is usually associated with improvement in the clinical symptoms, normalization cholesterol synthesis and reestablishment of selective permeability of blood-brain barrier with normalized CSF apolipoprotein and sterol concentrations.\textsuperscript{23} The absence of neurological dysfunction in other lipid disorders (familial hypercholesterolemia or sitosterolemia) further support the hypothesis that cholestanol itself impairs brain function.\textsuperscript{13}

It is important to remember that precocious diagnosis is fundamental due to the good response with chenodeoxycholic acid treatment reducing cholestanol accumulation and promoting lesion regression. The effectiveness of statins is controversial with the possibility of worsening the condition owing to increased low-density lipoprotein uptake as the result of augmented low-density lipoprotein
receptor activity\textsuperscript{13}. The detection of the specific mutation in each family is important to definitely confirm the diagnosis, to start treatment as earliest as possible, and to provide accurate genetic counseling to the patients and their family.

Acknowledgements - The authors wish to thanks Dr. Ana C. Bacelar Limeira from CETAC - Curitiba for neuroimage evaluation.

REFERENCES